Xiaonan Hou

Nuclear Cathepsin L Remodels the Replication Machinery to Create a Therapeutic Vulnerability in Ovarian Cancer

This paper identifies nuclear cathepsin L as a regulator of replication stress in ovarian cancer, showing that its activation creates a therapeutic vulnerability through replication machinery remodeling and DNA repair inhibition.

Drug-induced nuclear cathepsin L (nCTSL) defines a targetable DNA damage response axis and PARP inhibitor sensitivity in ovarian cancer

This study identifies nuclear cathepsin L (nCTSL) as a biomarker for PARP inhibitor sensitivity in ovarian cancer and shows that combining clofarabine with PARP inhibitors enhances therapeutic response.

Proteomic Analysis of PTEN-Deficient Cells Reveals Src-Mediated Upregulation of EphA2 and Therapeutic Potential of Dual Inhibition

This study identifies Src-mediated upregulation of EphA2 in PTEN-deficient cells and shows that combined AKT and Src inhibition synergistically suppresses tumor growth.

Lestaurtinib's antineoplastic activity converges on JAK/STAT signaling to inhibit advanced forms of therapy resistant ovarian cancer

This study identifies lestaurtinib as a potent inhibitor of ovarian cancer, effective against resistant models, by targeting JAK/STAT signaling and synergizing with standard therapies.

Single cell resolution of an epigenetic signature of persister tumor cell

The paper identifies an epigenetic signature associated with persister tumor cells in ovarian cancer that correlates with chemotherapy resistance and defines the persister state.